Natural history study of adults with primary central nervous system tumors: Initial results for first 1000 participants.

IF 2.5 Q2 CLINICAL NEUROLOGY
Neuro-oncology practice Pub Date : 2026-03-26 eCollection Date: 2026-08-01 DOI:10.1093/nop/npag026
Kimberly R Robins, Hope Miller, Michelle L Cassidy, Vivian A Guedes, Ewa Grajkowska, Tricia Kunst, Anna Choi, Alvina Acquaye-Mallory, Marta Penas-Prado, Jennifer Reyes, Kenneth Aldape, Mark R Gilbert, Elizabeth Vera, Terri S Armstrong
{"title":"Natural history study of adults with primary central nervous system tumors: Initial results for first 1000 participants.","authors":"Kimberly R Robins, Hope Miller, Michelle L Cassidy, Vivian A Guedes, Ewa Grajkowska, Tricia Kunst, Anna Choi, Alvina Acquaye-Mallory, Marta Penas-Prado, Jennifer Reyes, Kenneth Aldape, Mark R Gilbert, Elizabeth Vera, Terri S Armstrong","doi":"10.1093/nop/npag026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary central nervous system tumors (PCNST) are rare, understudied tumors for which knowledge of their clinical course, biology, physical, and psychological impact is limited. The National Cancer Institute's Neuro-Oncology Branch Natural History Study was developed to better understand the long-term disease course and outcomes experienced by these patients.</p><p><strong>Methods: </strong>Past medical histories, tumor tissue (if available), and patient-reported outcomes assessing symptom burden, general health status, anxiety, depression, and perceived cognitive deficits were collected at study enrollment. Sociodemographic, clinical, molecular, and patient-reported outcome data were analyzed descriptively.</p><p><strong>Results: </strong>Among the first 1000 participants, 796 had primary brain tumors (PBT) and 92 had primary spine tumors (PST); 88 were excluded. The cohort was predominantly male (56%), White (81%), and non-Hispanic (89%). Based on advanced molecular testing at enrollment, 190 (21%) patients had a change in diagnosis or subclassification since their initial diagnosis. Meningioma cases reported family brain tumor history more frequently than others. Most PBTs were diagnosed within 6 months of symptoms, while most PSTs were diagnosed ≥1 year after. Patients with PBT and PST reported an average of 10 symptoms, with 4 and 5 symptoms rated as moderate/severe, respectively. Nearly half of PBT participants reported anxiety or depression (46%) and difficulty with usual activities (48%). PST participants reported higher functional impairment and worse general health status.</p><p><strong>Conclusion: </strong>These findings underscore the substantial burden of PCNSTs and highlight the value of longitudinal, tumor-agnostic data in generating real-world insights into the disease trajectories of these rare and heterogeneous tumors to inform clinical research.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 4","pages":"743-758"},"PeriodicalIF":2.5000,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365162/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npag026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary central nervous system tumors (PCNST) are rare, understudied tumors for which knowledge of their clinical course, biology, physical, and psychological impact is limited. The National Cancer Institute's Neuro-Oncology Branch Natural History Study was developed to better understand the long-term disease course and outcomes experienced by these patients.

Methods: Past medical histories, tumor tissue (if available), and patient-reported outcomes assessing symptom burden, general health status, anxiety, depression, and perceived cognitive deficits were collected at study enrollment. Sociodemographic, clinical, molecular, and patient-reported outcome data were analyzed descriptively.

Results: Among the first 1000 participants, 796 had primary brain tumors (PBT) and 92 had primary spine tumors (PST); 88 were excluded. The cohort was predominantly male (56%), White (81%), and non-Hispanic (89%). Based on advanced molecular testing at enrollment, 190 (21%) patients had a change in diagnosis or subclassification since their initial diagnosis. Meningioma cases reported family brain tumor history more frequently than others. Most PBTs were diagnosed within 6 months of symptoms, while most PSTs were diagnosed ≥1 year after. Patients with PBT and PST reported an average of 10 symptoms, with 4 and 5 symptoms rated as moderate/severe, respectively. Nearly half of PBT participants reported anxiety or depression (46%) and difficulty with usual activities (48%). PST participants reported higher functional impairment and worse general health status.

Conclusion: These findings underscore the substantial burden of PCNSTs and highlight the value of longitudinal, tumor-agnostic data in generating real-world insights into the disease trajectories of these rare and heterogeneous tumors to inform clinical research.

成人原发性中枢神经系统肿瘤的自然历史研究:前1000名参与者的初步结果。
背景:原发性中枢神经系统肿瘤(PCNST)是一种罕见的、未被充分研究的肿瘤,对其临床过程、生物学、生理和心理影响的了解有限。国家癌症研究所的神经肿瘤学分支自然历史研究是为了更好地了解这些患者的长期病程和结果。方法:在研究入组时收集既往病史、肿瘤组织(如果有的话)和患者报告的结果,评估症状负担、一般健康状况、焦虑、抑郁和感知的认知缺陷。描述性地分析了社会人口学、临床、分子和患者报告的结果数据。结果:在前1000名参与者中,796名患有原发性脑肿瘤(PBT), 92名患有原发性脊柱肿瘤(PST);88例被排除在外。该队列以男性(56%)、白人(81%)和非西班牙裔(89%)为主。根据入组时的先进分子检测,190例(21%)患者自最初诊断以来诊断或亚分类发生了变化。脑膜瘤的家族史较其他病例多见。大多数pbt在症状出现6个月内被诊断,而大多数pst在症状出现≥1年后被诊断。PBT和PST患者平均报告10种症状,其中4种和5种症状分别被评为中度/重度。近一半的PBT参与者报告焦虑或抑郁(46%)和日常活动困难(48%)。PST参与者报告了更高的功能损害和更差的一般健康状况。结论:这些发现强调了pcnst的巨大负担,并强调了纵向的、肿瘤不可知的数据在产生对这些罕见和异质性肿瘤的疾病轨迹的真实见解方面的价值,从而为临床研究提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书